BioSpace News Archive

Genetown

Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome

Stealth BioTherapeutics Corp today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Adminstration (FDA) for elamipretide, the company’s lead product candidate, for the treatment of Barth syndrome, an ultra-rare genetic condition with no FDA- or EMA-approved therapies.

August 24, 2021
·
7 min read
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium

Alimera Sciences, Inc. announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, received pricing and reimbursement approval for ILUVIEN ® for diabetic macular edema (DME) in Belgium from the National Institute for Health and Disability Insurance (INAMI).

August 24, 2021
·
5 min read
Pharm Country

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing

Q BioMed Inc. is expected to receive a patent in Korea, adding to the already issued patents in Canada and Japan .

August 24, 2021
·
4 min read
Genetown

PerkinElmer to Present at 2021 Baird Global Healthcare Conference

PerkinElmer, Inc, today announced that the Company will present at the virtual Baird Global Healthcare Conference on Tuesday, September 14, 2021 at 10:50 a.m. ET.

August 24, 2021
·
1 min read
Pharm Country

Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing.

August 24, 2021
·
2 min read
Business

Cerba Research and ACT Genomics Announce Strategic Joint Venture — CerbACT Asia

Cerba Research announced today that they have joined forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.

August 24, 2021
·
2 min read
Drug Development

Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s DiseasePhase 3 Study Initiation Still Expected Fall 2021

Cassava Sciences, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 studies of oral simufilam for the treatment of patients with Alzheimer’s disease.

August 24, 2021
·
4 min read
Business

Novocardia™ Announces Key Additions to Leadership Team Accelerating Company’s Mission & Growth

Novocardia today announced the appointment of several new executive team members charged with accelerating the company’s mission to improve access to high-quality, high-value cardiovascular disease care.

August 24, 2021
·
4 min read
Biotech Bay

AllStripes Announces $50 Million Series B Financing to Advance Global Rare Disease Research

AllStripes today announced the Company completed a $50 million Series B financing round.

August 24, 2021
·
5 min read
Incyte Announces Health Canada Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte (Nasdaq: INCY) today announced that Health Canada has granted a Notice of Compliance with conditions for Minjuvi® (tafasitamab)

August 24, 2021
·
8 min read